Dr.Collins will present on the use of array comparative genomic hybridization (aCGH) and end sequence profiling (ESP) for the development of novel biomarkers and therapeutic targets for cancer.Prostate cancer is amongst the prevalent cancers in the Western world and is increasing in incidence.PSA screening for prostate cancer has resulted in stage migration so that increasingly tumors are detected at an earlier stage.Nonetheless the percentage of men diagnosed with tumors at an intermediate risk of progressing to metastasis has remained relatively constant at ~25% and there is little change in the outcome statistics for this group.